Advice
Following an abbreviated submission
daptomycin 500 mg powder for intravenous infusion (Cubicin®) is accepted for restricted use within NHS Scotland for the treatment of complicated skin and soft-tissue infections in adults.
Daptomycin should be restricted to use in patients with known or suspected methicillin-resistant Staphylococcus aureus (MRSA) infection and on the advice of local microbiologists or specialists in infectious disease.
The new strength allows patients weighing over 87.5 kg to be treated with a single 500mg vial at a reduced cost compared to two vials of the 350 mg strength.
Daptomycin has a higher acquisition cost than some alternative treatments; it does not, however, require therapeutic drug monitoring.
Download detailed advice29KB (PDF)
Medicine details
- Medicine name:
- daptomycin 500Â mg powder for intravenous infusion (Cubicin)
- SMC ID:
- 338/06
- Indication:
- Complicated skin and soft-tissue infections in adults
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 15 January 2007